Table 4.
Multivariate logistic regression of included clinical variables for 3-month functional outcome and 1-month mortality in PSM cohort.
| 3-month functional outcome | OR | 95% CI | P-value |
|---|---|---|---|
| GCS (per 1-point increase) | 0.611 | 0.508–0.736 | <0.001 |
| History of diabetes mellitus (yes vs. no) | 2.521 | 0.272–23.410 | 0.416 |
| Previous stroke (yes vs. no) | 6.588 | 0.689–62.985 | 0.102 |
| Hematoma volume (per 1-ml increase) | 1.034 | 1.012–1.057 | 0.002 |
| Hematoma location (supratentorial vs. infratentorial) | 1.725 | 0.682–4.361 | 0.250 |
| Presence of IVH (yes vs. no) | 1.837 | 0.614–5.499 | 0.277 |
| Treatment (surgical intervention vs. conservative treatment) | 2.326 | 0.925–5.849 | 0.073 |
| Neutrophil (per 1 × 109/L increase) | 1.143 | 1.030–1.269 | 0.012 |
| Monocyte (per 1 × 109/L increase) | 1.853 | 0.258–13.333 | 0.540 |
| NLR (per 1-point increase) | 1.076 | 1.016–1.139 | 0.012 |
| SIRI (per 1-point increase) | 1.312 | 1.096–1.571 | 0.003 |
| 1-month mortality | |||
| GCS (per 1-point increase) | 0.684 | 0.607–0.770 | <0.001 |
| Duration from onset to hospitalization (per 1-h increase) | 0.990 | 0.964–1.017 | 0.469 |
| Presence of hematoma expansion (yes vs. no) | 1.766 | 0.722–4.321 | 0.213 |
| Neutrophil (per 1 × 109/L increase) | 1.002 | 0.901–1.113 | 0.977 |
| Monocyte (per 1 × 109/L increase) | 35.970 | 4.490–288.130 | 0.001 |
| SIRI (per 1-point increase) | 1.153 | 1.050–1.265 | 0.003 |
OR, odds ratio; GCS, Glasgow Coma Scale; IVH, intraventricular hematoma; NLR, neutrophil-to-lymphocyte ratio; SIRI, systemic inflammation response index. Significant findings are expressed in bold and italic.